FDA Drug Safety Communication: Tysabri
The U.S. Food and Drug Administration (FDA) continues to evaluate the risk of progressive multifocal leukoencephalopathy ( PML ), a rare but serious brain infection, associated with use of Tysabri ( natalizumab ) for the treatment of multiple sclerosis (MS) and Crohn's disease.
Fabry Disease Affects Spanish Patients Differently
A disease may not affect all populations in an equal manner. A recent study shows that Spanish patients with a rare genetic metabolic disease do not necessarily exhibit the same symptoms as those in other European countries.